Transcode Therapeutics says DEFJ LLC files initial beneficial ownership statement
RNAZ•Filing and event dates
The event date was July 27, 2026; the filing date was Aug. 5, 2026.
Form 3 filing shows new 10% owner
Transcode Therapeutics disclosed a Form 3 filing showing DEFJ, LLC as a 10% owner with 300,040 common shares.
Preferred stock conversion holdings reported
The filing also reports direct holdings of Series A Non-Voting Convertible Preferred Stock convertible into 11,813,859 common shares.
Series B Non-Voting Convertible Preferred Stock was reported as convertible into 2,020,582 common shares.
